Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial

杜瓦卢马布 医学 耐受性 放化疗 内科学 临床终点 肺炎 危险系数 置信区间 阶段(地层学) 不利影响 外科 放射治疗 临床试验 癌症 彭布罗利珠单抗 免疫疗法 古生物学 生物
作者
Paolo Marchetti,Julien Mazières,Martin Reck,C. Chouaïd,Helge Bischoff,Niels Reinmuth,Laura Cove-Smith,T. Mansy,Diego Cortinovis,Maria Rita Migliorino,Angelo Delmonte,José Garcia Sánchez,Luis Enrique Chara Velarde,Reyes Bernabé,Luis Paz‐Ares,I. Diaz Perez,Nataliya Trunova,Kayhan Foroutanpour,C. Faivre‐Finn
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:17 (12): 1415-1427 被引量:57
标识
DOI:10.1016/j.jtho.2022.07.1148
摘要

IntroductionOn the basis of the findings of the phase 3 PACIFIC trial (NCT02125461), durvalumab is standard of care for patients with stage III, unresectable NSCLC and no disease progression after concurrent chemoradiotherapy (cCRT). Many patients are considered unsuitable for cCRT owing to concerns with tolerability. The phase 2 PACIFIC-6 trial (NCT03693300) evaluates the safety and tolerability of durvalumab after sequential CRT (sCRT).MethodsPatients with stage III, unresectable NSCLC and no progression after platinum-based sCRT were enrolled to receive durvalumab (1500 mg intravenously) every 4 weeks for up to 24 months. The primary end point was the incidence of grade 3 or 4 adverse events possibly related to treatment occurring within 6 months. Secondary end points included investigator-assessed progression-free survival (PFS; Response Evaluation Criteria in Solid Tumors version 1.1) and overall survival.ResultsOverall, 117 patients were enrolled (59.8% with performance status >0, 65.8% aged ≥65 y, and 37.6% with stage IIIA disease). Median treatment duration was 32.0 weeks; 37.6% of patients remained on treatment at data cutoff (July 15, 2021). Grade 3 or 4 AEs occurred in 18.8% of patients. Five patients had grade 3 or 4 possibly related adverse events within 6 months (incidence: 4.3%; 95% confidence interval: 1.4–9.7), including two pneumonitis cases. Two patients (1.7%) had grade 5 AEs of any cause. Survival data maturity was limited. Median PFS was 10.9 months (95% confidence interval: 7.3–15.6), and 12-month PFS and overall survival rates were 49.6% and 84.1%, respectively.ConclusionsDurvalumab after sCRT had a comparable safety profile with that observed with durvalumab after cCRT in PACIFIC and had encouraging preliminary efficacy in a frailer population.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
无语的断缘完成签到,获得积分10
3秒前
amwlsai完成签到,获得积分10
5秒前
闪闪青雪完成签到,获得积分10
5秒前
踏实大侠完成签到,获得积分10
5秒前
舒心老五发布了新的文献求助10
6秒前
小詹完成签到,获得积分10
6秒前
double完成签到,获得积分20
6秒前
6秒前
KUZZZ完成签到,获得积分10
6秒前
vivi发布了新的文献求助20
7秒前
外向行云完成签到,获得积分10
7秒前
慕青应助KUZZZ采纳,获得10
10秒前
高大绝义完成签到,获得积分10
10秒前
而当下的完成签到,获得积分10
10秒前
markerfxq完成签到,获得积分10
11秒前
KrisTina完成签到 ,获得积分10
11秒前
11秒前
11秒前
科研肥料发布了新的文献求助10
11秒前
顺心醉蝶完成签到 ,获得积分10
12秒前
美满的砖头完成签到 ,获得积分10
12秒前
sunflowers完成签到 ,获得积分10
12秒前
勤恳的书文完成签到 ,获得积分10
13秒前
直率心锁完成签到,获得积分10
13秒前
孙非完成签到,获得积分10
14秒前
和平发展完成签到,获得积分10
14秒前
雪落你看不见完成签到,获得积分10
14秒前
成成成岩浆完成签到 ,获得积分10
15秒前
自然归尘完成签到 ,获得积分10
15秒前
LILYpig完成签到 ,获得积分10
16秒前
aaaaaa发布了新的文献求助10
16秒前
17秒前
伴奏小胖完成签到 ,获得积分10
17秒前
里埃尔塞因斯完成签到 ,获得积分10
18秒前
19秒前
20秒前
无味完成签到,获得积分10
20秒前
Jasper应助舒心老五采纳,获得10
20秒前
笋尖266完成签到,获得积分10
20秒前
科研通AI2S应助aaaaaa采纳,获得10
20秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968578
求助须知:如何正确求助?哪些是违规求助? 3513406
关于积分的说明 11167631
捐赠科研通 3248853
什么是DOI,文献DOI怎么找? 1794499
邀请新用户注册赠送积分活动 875150
科研通“疑难数据库(出版商)”最低求助积分说明 804671